Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong joins Jonathan Jackson in the Proactive studio this morning to discuss encouraging results from the company’s Phase 1 Metastatic Advanced Solid Tumours trial, evaluating the safety and efficacy of its novel cancer-killing virus CF33-hNIS (VAXINIA). In exceptional news for the company, one patient with biliary tract cancer achieved a Complete Response after being treated at a mid-dose level and has remained in remission for over 430 days. Two Partial Responses were also observed in melanoma patients at a mid-dose level. Imugene will now move to a dose escalation phase. Early results were presented at the American Society of Clinical Oncology - Gastrointestinal Cancer Symposium (ASCO-GI) in San Francisco, California. Chong discusses what that means for the company and what shareholders can expect in 2024.
Imugene achieves ‘complete response’ with mid dose cancer trial
